Biomarker

Biomarker - Axcellant

Biomarker

  1. lut 28, 2025

What Does 'Biomarker’ Mean?

A biomarker is a measurable indicator of a biological state or condition. It can be a molecule, gene, characteristic, or substance that can be objectively measured and evaluated as a sign of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention.

Biomarkers are widely used in clinical research and medical practice to assess health states, disease risk, or treatment effectiveness. They can be found in various biological samples such as blood, urine, or tissue, and may include genetic markers, proteins, hormones, or specific cellular changes.

Why Is the 'Biomarker’ Important in Clinical Research?

Biomarkers play a crucial role in clinical research by providing objective, quantifiable data about biological processes and drug responses. They enable researchers to assess the safety and efficacy of new treatments more accurately and efficiently, potentially reducing the time and cost of drug development.

Furthermore, biomarkers can help identify suitable patients for clinical trials, improving study design and increasing the likelihood of successful outcomes. They also contribute to the development of personalized medicine by allowing healthcare providers to tailor treatments based on individual patient characteristics and responses.

Good Practices and Procedures

  1. Validate biomarker assays for reproducibility and accuracy across different laboratories before implementation in clinical trials
  2. Establish clear criteria for biomarker positivity or threshold values, accounting for biological variability and analytical precision
  3. Incorporate biomarker collection and analysis plans into clinical trial protocols, specifying timing, sample handling, and storage procedures
  4. Conduct regular quality control checks on biomarker data to identify potential outliers or systematic errors
  5. Develop standardized reporting formats for biomarker results to facilitate data interpretation and cross-study comparisons

Related Terms

Read more

Axcellant partners with Prometheus MedTech.AI to accelerate AI-powered cardiac diagnostics

We’re pleased to announce a strategic partnership between Axcellant and Prometheus MedTech.AI — a medtech startup developing AI-powered solutions for…

Axcellant at EANM 2025: What We Brought Back from Barcelona

The Axcellant team has returned from the European Association of Nuclear Medicine (EANM) Annual Congress in Barcelona — and it’s…

Radioisotopes in Medicine: Clinical Applications, Safety, and Regulatory Considerations

The robust development of nuclear medicine depends on the availability of radioactive isotopes, some of which are used for diagnostic…